Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BGI Genomics Re-Files to Raise $250 Million in Shenzhen IPO

publication date: Mar 15, 2017
BGI Genomics, the Shenzhen genomics sequencing company, has filed to IPO on the Shenzhen Chi-Next exchange with a proposed target of raising $250 million. Late last year, the Shenzhen Exchange rejected a similar application from BGI Genomics because its documentation was not complete. The previous transaction was rumored to be much larger -- about $600 million. BGI Genomics, a division of BGI Holdings, includes several of BGI's revenue producing divisions, such as BGI Tech, its contract genomics sequencing service subsidiary, and BGI Dx, its clinical diagnostic division. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital